Clinical significance of sFlt-1/PlGF in the diagnosis and prediction of preeclampsia
- Authors: Guryeva V.M.1, Travkina A.A.1, Matveev M.O.1, Morokhotova L.S.1, Budykina T.S1, Kotov Y.B.2, Semenova T.A.3
-
Affiliations:
- Moscow Regional Research Institute of Obstetrics and Gynecology
- Federal Research Center, M.V. Keldysh Institute of Applied Mathematics, Russian Academy of Sciences
- National Research Nuclear University, Moscow Engineering and Physical Institute
- Issue: No 7 (2021)
- Pages: 195-200
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249500
- DOI: https://doi.org/10.18565/aig.2021.7.195-200
- ID: 249500
Cite item
Abstract
Full Text
About the authors
Vera M. Guryeva
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: helgin99@gmail.com
Dr. Med. Sci., Leading Researcher
Arina A. Travkina
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: arinamamba@mail.ru
PhD, Senior Researcher
Maxim O. Matveev
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: max-mix@mail.ru
graduate student
Ludmila S. Morokhotova
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: ludrikm1982@gmail.com
PhD, doctor
T. S Budykina
Moscow Regional Research Institute of Obstetrics and Gynecology
Yury B. Kotov
Federal Research Center, M.V. Keldysh Institute of Applied Mathematics, Russian Academy of Sciences
Email: kobylazabyla11@yandex.ru
Dr. Sci. (Physics and Mathematics), Leading Researcher
Tatyana A. Semenova
National Research Nuclear University, Moscow Engineering and Physical Institute
Email: kotsem@voxnet.ru
PhD (Physics and Mathematics), Associate Professor
References
- Say L., Chou D., Gemmill A., Tunca1р O., Moller A.-B., Daniels J. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob. Health. 2014; 2: e323-33. https://dx.doi.org/10.1016/S2214-109X(14)70227-X.
- Шалина Р.И., Михалева Л.М., Симухина М.А., Коноплянников А.Г., Штабницкий А.М. Особенности течения тяжелых форм преэклампсии в современных условиях. Вопросы гинекологии, акушерства и перинатологии. 2017; 16(6): 16-23. https://dx.doi.org/10.20953/1726-1678-2017-6-16-23.
- Sibai B.M., Stella C.L. Diagnosis and management of atypical preeclampsia-eclampsia. Am. J. Obstet. Gynecol. 2009; 200(5): 481. e1-7. https://dx.doi.org/10.1016/j.ajog.2008.07.048.
- Сидорова И.С., Никитина Н.А., Унанян А.Л. Преэклампсия и снижение материнской смертности в России. Акушерство и гинекология. 2018; 1: 107-12. [Sidorova I.S., Nikitina N.A., Unanyan A.L. Preeclampsia and reduction of maternal mortality in Russia. Obstetrics and gynecology. 2018; 1: 107-11. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.1.107-112.
- Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003; 111(5): 649-58. https://dx.doi.org/10.1172/JCI17189.
- Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006; 355(10): 992-1005. https://dx.doi.org/10.1056/NEJMoa055352.
- Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 2004; 95(9): 884-91. https://dx.doi.org/10.1161/01.RES.0000147365.86159.f5.
- Palm M., Basu S., Larsson A., Wernroth L., Kerud H., Axelsson O. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstet. Gynecol. Scand. 2011; 90(11): 1244-51. https://dx.doi.org/10.1111/j.1600-0412.2011.01186.x.
- Иванец Т.Ю., Алексеева М.Л., Логинова Н.С., Колодько В.Г., Насонова Д.М., Хасьянова З.Ш. Плацентарный фактор роста и fms-подобная тирозинкина-за-1 как маркеры преэклампсии в динамике беременности. Клиническая лабораторная диагностика. 2013; 8: 14-7.
- Verlohren S., Galindo A., Schlembach D., Zeisler H., Herraiz I., Moertl M.G. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2010; 202(2): 161. e1. 161. e11. https://dx.doi.org/10.1016/j.ajog.2009.09.016.
- Verlohren S., Herraiz I., Laрaire O., Schlembach D., Moertl M., Zeisler H. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J. Obstet. Gynecol. 2012; 206(1): 58. e1-8. https://dx.doi.org/10.1016/j.ajog.2011.07.037.
- Rana S., Powe C.E., Salahuddin S., Verlohren S., Perschel F.H., Levine R.J. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012; 125(7): 911-9. https://dx.doi.org/10.1161/ CIRCULATIONAHA.111.054361.
- Gomez-Arriaga P., Herraiz I., Loрez-Jimenez E.A., Escribano D., Denk B., Galindo A. Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset preeclampsia. Ultrasound Obstet. Gynecol. 2014; 43(5): 525-32. https://dx.doi.org/10.1002/uog.13224.
- Курцер М.А., Шаманова М.Б., Синицына О.В., Николаев А.А., Николаева Е.В., Дедловская А.И., Самсонова М.А. Использование тест-системы Elecsys PlGF и sFLT-1 с целью прогнозирования перинатальных исходов у пациенток с тяжелой преэклампсией. Акушерство и гинекология. 2019; 10: 96-104. https://dx.doi.org/10.18565/aig.2019.10.162-170.
- Verlohren S., Herraiz I., Laрaire O., Schlembach D., Zeisler H., Calda P. et al. New gestational phase- specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014; 63(2): 346-52. https://dx.doi.org/10.1161/ HYPERTENSIONAHA.113.01787.
- Simon E., Permuy C., Sacristan L., Zamoro-Lorenci M.J., Villalain C., Galindo A., Herraiz I. sFlt-1/PlGF ratio for the prediction of delivery within 48 hours and adverse outcomes in expectantly managed early-onset preeclampsia. Pregnancy Hypertens. 2020; 22: 17-23. https://dx.doi.org/10.1016/j.preghy.2020.07.007.
- Tasta O., Parant O., Hamdi S.M., Allouche M., Vayssiere C., Guerby P. Evaluation of the prognostic value of the sFlt-1/PlGF ratio in early-onset preeclampsia. Am. J. Perinatol. 2020 May 23. https://dx.doi.org/10.1055/s-0040-1709696.
- Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A. C., Sennstrom M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016; 374(1): 13-22. https://dx.doi.org/10.1056/ NEJMoa1414838.
- Bian X., Biswas A., Huang X., Lee K., Kwok-To Li T., Masuyama H. et al. Shortterm prediction of adverse outcomes using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) ratio in Asian women with suspected preeclampsia. Hypertension. 2019; 74(1): 164-72. https://dx.doi.org/10.1161/ HYPERTENSIONAHA.119.12760.
- Sabria E., Lequerica-Fernandez P., Ganuza P.L., Angeles E.E., Escudero A.I., Martinez-Morillo E., Alvarez F.V. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible? Chem. Lab. Med. 2018; 56(2): 303-11. https://dx.doi.org/10.1515/cclm-2017-0443.
- Курцер М.А., Шаманова М.Б., Синицина О.В., Николаева А.А., Дедловская А.И., Самсонова М.А. Клиническое обоснование определения соотношения sFlt-1/PlGF с целью раннего выявления и оценки степени тяжести преэклампсии. Акушерство и гинекология. 2018; 11: 114-20. doi.org/10.18565/ aig.2018.11.114-120.
- Ходжаева З.Х., Холин А.М., Шувалова М.П., Иванец Т.Ю., Демура С.А., Галичкина И.В. Российская модель оценки эффективности теста на преэклампсию sFlt-1/PlGF. Акушерство и гинекология. 2019; 2: 52-8. [Khodzhaeva Z.S., Kholin A.M., Shuvalova M.P., Ivanets T.Yu., Demura S.A., Galichkina I.V. A Russian model for evaluating the efficiency of the sFlt-1/PlGF test for preeclampsia. Obstetrics and Gynecology. 2019; 2: 52-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.2.52-58
- Беженарь В.Ф., Смирнов А.В., Тимирбулатов Р.Р., Габелова К.А., Шапкайц В.А., Нестеров И.М. Почечная дисфункция при преэклам псии: прогнозирование и дифференциальный диагноз. Часть 1. Доктор. Ру. 2020; 19(6): 23-9. https://dx.doi.org/10.31550/1727-2378-2020-19-6-23-29.
- Никольская И.Г., Прокопенко Е.И., Ватазин А.В., Будыкина Т.С. Ангиогенные и антиангиогенные факторы у беременных с хронической болезнью почек: роль коэффициента sFlt-1/PlGF в прогнозировании и диагностике преэклампсии. Нефрология и диализ. 2016; 18(4): 440-51.
- Agrawal S., Cerdeira A. S., Redman C., Vatish M. Meta-ana lysis and systematic review to assess the role of soluble FMS-like tyrosinekinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study. Hypertension. 2018; 71(2): 306-16. https://dx.doi.org/10.1161/ HYPERTENSI0NAHA.117.10182.
- Приказ Министерства здравоохранения Московской области № 1072 от 23.07.2018 «Об организации работы по раннему скринингу преэклампсии у беременных в Московской области».
- Stepan H., Hund M., Dilba P., Sillman J., Schlembach D. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable? Clin. Chem. Lab. Med. 2019; 57(9): 1339-48. https://dx.doi.org/10.1515/cclm-2018-1228.
- Резолюция Совета экспертов «Нормативный регламент и вопросы организации скрининга и прогнозирования преэклампсии в РФ». Акушерство и гинекология. 2021; 5: 219-21. [Resolution of the Council of Experts "Regulatory guidelines and issues relating to the organization of screening and prediction of preeclampsia in the Russian Federation". Obstetrics and Gynecology. 2021; 5: 219-21. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.5.219-221.